Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy
- Details
- Publication Year 2024-06,Volume 44,Issue #3,Page e438658
- Journal Title
- American Society of Clinical Oncology Educational Book
- Publication Type
- Review
- Abstract
- The management of renal cell carcinoma (RCC) has advanced significantly in the past two decades. Many promising functional imaging modalities such as radiolabeled tracer targeting carbonic anhydrase IX and prostate-specific membrane antigen are under development to detect primary kidney tumors, stage systemic disease, and assess treatment response in RCC. Immune checkpoint inhibitors targeting PD-1 and cytotoxic T-cell lymphocyte-4 have changed the treatment paradigm in advanced RCC. Trials investigating novel mechanisms such as LAG-3 immune checkpoint inhibition, chimeric antigen receptor T-cell therapies, and T-cell engagers targeting RCC-associated antigens are currently ongoing. With the rapidly changing treatment landscape of RCC, the treatment sequence strategies will continue to evolve. Familiarity with the toxicities associated with the therapeutic agents and how to manage them are essential to achieve optimal patient outcomes. This review summarizes the recent developments of functional imaging and immunotherapy strategies in RCC, and the evidence supports treatment sequencing.
- Publisher
- American Society of Clinical Oncology
- Keywords
- Humans; *Carcinoma, Renal Cell/therapy; *Immunotherapy/methods; *Kidney Neoplasms/therapy; Immune Checkpoint Inhibitors/therapeutic use
- Department(s)
- Radiation Oncology
- Publisher's Version
- https://doi.org/10.1200/edbk_438658
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-30 06:26:11
Last Modified: 2024-07-30 06:34:07